跳至主要内容

Medicilon Tumor Animal Model Debut

 SAPA-DC 2017 Annual Scientific Seminar came to an end in Rockville, Maryland, USA on April 1, 2017.

During the meeting, Dr. Wang Jun, VP of Medicilon’s biology department, gave his speech on the “Animal Models in Drug Discovery on Immunotherapy at Medicilon”. He shared the latest developments of tumor animal model and part of technical data of Medicilon.

The conference gathered in the field of scientific research, clinical practice of medicine and policy supervision and other fields of experts and scholars on the scene of the most cutting-edge cancer immunotherapy.  The 200 experts and scholars travelled from Maryland, Pennsylvania, New Jersey and China’s domestic pharmaceutical industry.

As an important business partner of the seminar, Dr. Wang Jun said, “It is a great honor to be able to introduce Medicilon’s entire animal model library, including the tumor animal model to the world’s regional pharmaceutical industry counterparts.

Medicilon attaches great importance to the pharmaceutical research and development technology to make sure that we master the cutting edge techniques of this part.

Medicilon has attended a lot of large academic exchange meeting such as SAPA. Collaboration and win-win are our mission as well as our vision of globalization.

Medicilon has a complete animal model library, including more than 200 kinds of tumor models and 50 kinds of disease models available for domestic and foreign customers.

On the more popular models in recent years, such as orthotropic transplantation model, humanized tumor transplantation model, genetically modified model and etc., Medicilon’s current level of technology for them is mature and stable.

Followings are the part of contents from Dr. Wang Jun speech:

Xenograft Models (cellular therapy)

Syngeneic ModelsSyngeneic Mouse model (efficacy study)

PD studyFCM Data Analysis

FCM Phenotypic Analysis

FCM Panel Design

Pharmacology Services

other animal model at medicilonother animal models at medicilon

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文